Minimal Residual Disease in Mantle Cell Lymphoma: Methods and Clinical Significance

Marco Ladetto; Rita Tavarozzi; Christiane Pott

doi:10.1016/j.hoc.2020.06.006

Minimal Residual Disease in Mantle Cell Lymphoma: Methods and Clinical Significance

Marco Ladetto, Rita Tavarozzi, Christiane Pott

Risultato della ricerca: Contributo su rivista › Articolo di review › peer review

Abstract

Several biological and clinical features have been recognized in mantle cell lymphoma (MCL). In recent years, the minimal residual disease (MRD) has been extensively investigated and is now considered as one of the strongest clinical predictors in this lymphoma. This article reviews methods used for the assessment of MRD in MCL and discusses their strengths and weaknesses. In addition, it examines the MRD contribution to the biology knowledge of MCL and the development of effective strategies for its management, including the possibility of personalized treatment based on MRD response.

Lingua originale	Inglese
pagine (da-a)	887-901
Numero di pagine	15
Rivista	Hematology/Oncology Clinics of North America
Volume	34
Numero di pubblicazione	5
DOI	https://doi.org/10.1016/j.hoc.2020.06.006
Stato di pubblicazione	Pubblicato - ott 2020
Pubblicato esternamente	Sì

Accesso al documento

10.1016/j.hoc.2020.06.006

Altri file e collegamenti

Link to publication in Scopus

Cita questo

@article{2022633b035649179d15c689c3bf1b5b,

title = "Minimal Residual Disease in Mantle Cell Lymphoma: Methods and Clinical Significance",

abstract = "Several biological and clinical features have been recognized in mantle cell lymphoma (MCL). In recent years, the minimal residual disease (MRD) has been extensively investigated and is now considered as one of the strongest clinical predictors in this lymphoma. This article reviews methods used for the assessment of MRD in MCL and discusses their strengths and weaknesses. In addition, it examines the MRD contribution to the biology knowledge of MCL and the development of effective strategies for its management, including the possibility of personalized treatment based on MRD response.",

keywords = "Molecular relapse, Molecular response, Next-generation sequencing, Polymerase chain, Reaction",

author = "Marco Ladetto and Rita Tavarozzi and Christiane Pott",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = oct,

doi = "10.1016/j.hoc.2020.06.006",

language = "English",

volume = "34",

pages = "887--901",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders Ltd",

number = "5",

}

TY - JOUR

T1 - Minimal Residual Disease in Mantle Cell Lymphoma

T2 - Methods and Clinical Significance

AU - Ladetto, Marco

AU - Tavarozzi, Rita

AU - Pott, Christiane

PY - 2020/10

Y1 - 2020/10

N2 - Several biological and clinical features have been recognized in mantle cell lymphoma (MCL). In recent years, the minimal residual disease (MRD) has been extensively investigated and is now considered as one of the strongest clinical predictors in this lymphoma. This article reviews methods used for the assessment of MRD in MCL and discusses their strengths and weaknesses. In addition, it examines the MRD contribution to the biology knowledge of MCL and the development of effective strategies for its management, including the possibility of personalized treatment based on MRD response.

AB - Several biological and clinical features have been recognized in mantle cell lymphoma (MCL). In recent years, the minimal residual disease (MRD) has been extensively investigated and is now considered as one of the strongest clinical predictors in this lymphoma. This article reviews methods used for the assessment of MRD in MCL and discusses their strengths and weaknesses. In addition, it examines the MRD contribution to the biology knowledge of MCL and the development of effective strategies for its management, including the possibility of personalized treatment based on MRD response.

KW - Molecular relapse

KW - Molecular response

KW - Next-generation sequencing

KW - Polymerase chain

KW - Reaction

UR - http://www.scopus.com/inward/record.url?scp=85089069121&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2020.06.006

DO - 10.1016/j.hoc.2020.06.006

M3 - Review article

SN - 0889-8588

VL - 34

SP - 887

EP - 901

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

IS - 5

ER -

Minimal Residual Disease in Mantle Cell Lymphoma: Methods and Clinical Significance

Abstract

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo